The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2021.27.6.797
Abstract: DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER),… read more here.
Keywords: health care; value nadofaragene; effectiveness value; health ... See more keywords